About me
My name is Dr. Iris Bresink, and I am a medical and regulatory writer with over 25 years of experience in clinical research and regulatory affairs. Throughout my career, I have had the privilege of collaborating with leading pharmaceutical companies, contributing to the successful approval of several major drugs across a variety of therapeutic areas.
My expertise includes developing and authoring a wide range of regulatory and clinical documents, such as New Drug Applications (NDAs), Biologic License Applications (BLAs), Marketing Authorization Applications (MAAs), and Investigational New Drug Applications (INDs). I strive to provide clear, accurate, and impactful writing to support your regulatory submissions and ensure a smooth approval process.
My goal is to simplify complex scientific concepts and ensure your work meets regulatory requirements for success.
Therapeutic Areas of Expertise
- Women’s Health
- Hematology
- Oncology
- Men’s Health
- Respiratory Conditions
- Gastroenterology
- Rare Diseases
- Dermatology
- Immunology
- Gene Therapy
- Pain Management
Professional Milestones
This overview highlights key stages of my career. For my full CV, please contact me.
Development and authorship of key regulatory submission documents including clinical study protocols and reports, clinical overviews and summaries (CTD Modules 2.5 and 2.7), briefing books, investigator’s brochures, and regulatory responses across multiple therapeutic areas.
Workshop Leader at European Medical Writers Association (since 2025).
Germany
Led submission strategies for NDAs, BLAs, and MAAs of new molecular entities and life-cycle management of approved products. Authored clinical overviews and summaries, briefing books, PIPs, clinical study reports, and post-approval documents. Established a lean medical writing approach and provided cross-functional document support.
Bayer AG Wuppertal, Germany
Responsible for clinical CTD strategy, authoring clinical overviews and summaries, briefing books, and responses to Health Authorities for new molecular entities and life-cycle management (FDA, EMA, worldwide).
Schering AG, Berlin, Germany
Managed mutual recognition procedures in gastroenterology and prepared and submitted post-registration documentation for affected products.
ASCHE AG, Hamburg, Germany
University of Bristol, Medical School, Bristol, UK, and Schering AG, Berlin, Germany
Institute of Pharmacology, University of Frankfurt/Main, Germany
University of Frankfurt/Main, Germany